The above results supported the therapeutic potential of eIF4E in AML in the absence of ATRA or ATPR in vitro, we then aimed to determine the role of eIF4E in vivo by establishing an AML xenograft model (Figure 3A). The gene discussed is EIF4E; the disease is acute myeloid leukemia.